Lantern Pharma Inc.
NASDAQ:LTRN

Watchlist Manager
Lantern Pharma Inc. Logo
Lantern Pharma Inc.
NASDAQ:LTRN
Watchlist
Price: 3.072 USD -1.85% Market Closed
Market Cap: 33.1m USD
Have any thoughts about
Lantern Pharma Inc.?
Write Note

Lantern Pharma Inc.
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lantern Pharma Inc.
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Lantern Pharma Inc.
NASDAQ:LTRN
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$1.6B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$10B
CAGR 3-Years
-242%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
$243m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$4.6B
CAGR 3-Years
N/A
CAGR 5-Years
-175%
CAGR 10-Years
-51%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$219.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-35%
No Stocks Found

Lantern Pharma Inc.
Glance View

Market Cap
33.1m USD
Industry
Biotechnology

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.

LTRN Intrinsic Value
3.831 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

Back to Top